Formulation and Evaluation of Amikacin Sulfate Loaded Dextran Nanoparticles against Human Pathogenic Bacteria

Amikacin sulfate-loaded dextran sulfate sodium nanoparticles were formulated, lyophilized (LADNP), and then analyzed. The LADNP had a -20.9 +/- 8.35 mV zeta potential, PDI of 0.256, and % PDI of 67.7. The zeta average nano size of LADNP was 317.9 z. d.nm, while the dimension of an individual particle was 259.3 +/- 73.52 nm, and nanoparticle conductivity in colloidal solution was 2.36 mS/cm. LADNP has distinct endothermic peaks at temperatures at 165.77 degrees C, according to differential scanning calorimetry (DSC). The thermogravimetric analysis (TGA) showed the weight loss of LADNP, which was observed as 95% at 210.78 degrees C. XRD investigation on LADNP exhibited distinct peaks at 2 theta as 9.6 degrees, 10.4 degrees, 11.4 degrees, 18.9 degrees, 20.3 degrees, 24.4 degrees, 28.2 degrees, 33.2 degrees, 38.9 degrees, and 40.4 degrees confirming crystalline structure. The amikacin release kinetics from LADNP revealed zero order kinetics with a linear release showed zero order kinetics with 37% of drug release in 7 h and had an R-2 value of 0.99. The antibacterial effect of LADNP showed broad-spectrum activity against tested human pathogenic bacteria. The preset study demonstrated that LADNP is a promising antibacterial agent.

Automated summary

Amikacin sulfate-loaded dextran sulfate sodium nanoparticles (LADNP) were prepared and analyzed. LADNP had a zeta potential of -20.9 +/- 8.35 mV, PDI of 0.256, and % PDI of 67.7. The size of LADNP was 317.9 d. nm, with individual particles measuring 259.3 +/- 73.52 nm. The release kinetics of amikacin from LADNP demonstrated zero order kinetics, with 37% of the drug released in 7 hours.